Partner portal 
19001717 Metascreen™ is a highly reliable newborn screening test that utilizes gas chromatography-mass spectrometry (GC-MS) technology to detect metabolic disorders.
FDA-approved method using urine samples to identify chemical compounds.
The gold standard in the analysis of lipids, drug metabolites, and environmental factors.
Detects over 250 compounds in urine to screen for more than 100 inherited metabolic disorders (IEM) in newborns.
High accuracy – GC-MS technology separates interfering compounds (such as medications) excreted in urine to ensure report integrity.
Comprehensive analysis – Each disorder is identified by analyzing multiple biochemical markers.
Rigorous calibration – The test is benchmarked against normal sample databases from both regional and global populations to detect abnormal cases.
